Please login to the form below

Not currently logged in
Email:
Password:

RTS,S

This page shows the latest RTS,S news and features for those working in and with pharma, biotech and healthcare.

GSK cues up regulatory filings for relapsing malaria drug

GSK cues up regulatory filings for relapsing malaria drug

One of the greatest challenges for patients with P vivax malaria is preventing relapses," said GSK's president of R&D Patrick Vallance. ... GSK is also developing a four-dose vaccine for malaria - RTS, S/AS01 - that has shown 31-56% protective efficacy

Latest news

  • Dosing of GSK's malaria vaccine due to start in 2018 Dosing of GSK's malaria vaccine due to start in 2018

    Funding has now been secured for vaccination programmes using GlaxoSmithKline's malaria vaccine RTS, S, with the people due to receive the shots in 2018. ... RTS, S, acts against Plasmodium falciparum, the most deadly malaria parasite globally and the

  • Malaria vaccine is first to provide 'sustained protection' Malaria vaccine is first to provide 'sustained protection'

    The vaccine is based on inactivated Plasmodium falciparum sporozoites, a key stage in the parasite's life cycle. ... Mosquirix (formerly known as RTS, S) also targets P. falciparum - the most virulent form of malaria which affects 214m people a year and

  • World first as CHMP backs GSK malaria vaccine Mosquirix World first as CHMP backs GSK malaria vaccine Mosquirix

    World first as CHMP backs GSK malaria vaccine Mosquirix. The EMA's scientific advisers recommend its useoutside Europe. ... Formerly known as RTS, S/ASO1, Mosquirix (Plasmodium falciparum and hepatitis B vaccine) was assessed under EMA rules that allow

  • Sharing knowledge to combat emerging threats Sharing knowledge to combat emerging threats

    GSK's work on a malaria vaccine is a good example of this. ... The company's RTS, S vaccine, filed for regulatory approval in Europe last year, is designed to protect against Plasmodium falciparum, the most dangerous of the mosquito-borne malaria

  • GSK squares up to Merck with shingles vaccine data GSK squares up to Merck with shingles vaccine data

    GlaxoSmithKline (GSK) has reported positive phase III trial data for a new shingles vaccine that could be the first major competitor to Merck &Co's Zostavax. ... HZ/su also includes Agenus' AS01B adjuvant, which was also used in the company's RTS vaccine

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics